Inclusion criteria
|
1. Selection criteria: Subjects must meet all of the following selection criteria to enter the introduction period:
1) Females or males aged ≥ 18;
2) Renal biopsy confirms primary IgA nephropathy;
3) 24-hour urine protein quantitative ≥ 0.75 g, or urine protein creatinine ratio (UPCR) ≥ 0.5 g/g;
4) 59≥eGFR≥ 30mL/min/1.73 m2 calculated using the CKD-EPI cooperative creatinine formula (CKD-EPI2009);
5) Males with fertility and female subjects of childbearing age are required to use effective contraception between the time of signing the informed until the end of the trial; Female subjects of childbearing age included women who had not been menopausal and who had not been menopause for more than 2 years; Male subjects were required to agree not to donate sperm during the study period;
6) Be able to sign an informed consent form, understand and agree to comply with the requirements of the study and the trial process arrangement.
|
Exclusion criteria:
|
Subjects with any of the following items cannot be screened or enter the introduction phase:
1) Systemic diseases that can cause IgA deposition in the mesangial region of the glomeruli, including but not limited to: Henoch-Sch?nlein purpura, systemic lupus erythematosus, ankylosing spondylitis, etc.; Special types of IgA nephropathy (including minimal lesions with mesenteric IgA deposition, rapidly progressive crescent IgA nephropathy, etc.) and other glomerular diseases (such as diabetes nephropathy, etc.);
2) 24-hour urine protein quantitative >5g;
3) Renal biopsy shows a crescent body ratio of ≥25%; History of severe gastrointestinal disorders (e.g., active peptic ulcer disease, active gastrointestinal bleeding, history of gastrointestinal perforation, inflammatory bowel disease, chronic diarrhea, etc.); or other conditions that the researcher judges may affect the effectiveness of the drug
4) severe chronic or active infection (including but not limited to tuberculosis infection) in the treatment;
5) Subjects with unstable angina or a history of grade III or IV congestive heart failure or clinically significant arrhythmias;
6) Subjects diagnosed with malignancy in the past 5 years, except for locally recurrent cancers that have been cured (such as basal cell or squamous cell skin cancer, superficial bladder cancer, cervical cancer in situ or breast cancer, etc.);
7) Subjects with a history of cirrhosis; Subjects with severe osteoporosis who need to be treated; Subjects who have received organ transplantation; Subjects with glaucoma or cataracts who are currently undergoing clinical treatment; Subjects diagnosed with uncontrolled mental illness;
8) Subjects with poor control of type 1 or type 2 diabetes mellitus (glycosylated hemoglobin >8%);
9) Laboratory tests for abnormal liver function (ALT and/or AST> 2 times the upper limit of normal values, ALP > 2.5 times the upper limit of normal values);
10) Laboratory test for serious abnormalities of total blood cholesterol (>500mg/dL or >12.92mmol/L); Positive antibodies for human immunodeficiency virus, positive treponemal antibodies, positive for hepatitis B surface antigen, positive for hepatitis C antibodies;
11) Received immunosuppressive drugs other than glucocorticoids within 6 months before the screening period;
12) Received any systemic glucocorticoid therapy within 3 months prior to the screening period;
13) is known to be oversensitive or intolerant to any ingredient of valsartan or a pharmaceutical formulation for experimental purposes;
14) Subjects with a long history of alcohol consumption (defined as drinking 2 servings of alcoholic beverages per day > or 14 servings per week >; One alcoholic beverage is defined as 150ml of wine, 350ml of beer, or 50ml of liquor) or a history of heavy drinking in the 2 weeks prior to screening (defined as drinking 4 alcoholic drinks per day> or 28 servings per week >);
15) Female subjects during pregnancy or breastfeeding;
16) Depending on the investigator's decision, there are other medical or social reasons that lead to the subject's exclusion
|